Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B D Anderson

Showing results (81-90 of 156) with videos related to

Pageof 16
Sort By:
Antimicrobial Agents and Chemotherapy|May 1, 1994
Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteinsS Kageyama, B D Anderson, B L Hoesterey, et al.
American Journal of Human Genetics|March 21, 2000
Exon skipping in IVD RNA processing in isovaleric acidemia caused by point mutations in the coding region of the IVD geneJ Vockley, P K Rogan, B D Anderson, et al.
Annals of the New York Academy of Sciences|January 1, 1983
Immunosuppression by human alpha 2-macroglobulin, a 3800 Mr peptide, and other derivativesW J Hubbard, B D Anderson, A E Balber, et al.
Pediatrics|October 4, 2000
Prospective evaluation of propofol anesthesia in the pediatric intensive care unit for elective oncology procedures in ambulatory and hospitalized childrenJ H Hertzog, H J Dalton, B D Anderson, et al.
The Journal of Infectious Diseases|May 1, 1995
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapyE Kojima, T Shirasaka, B D Anderson, et al.
Journal of Medicinal Chemistry|June 26, 1992
Synthesis and anti-HIV activity of isonucleosidesD M Huryn, B C Sluboski, S Y Tam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2014
The role of age on dose-limiting toxicities in phase I dose-escalation trialsA Schwandt, P J Harris, S Hunsberger, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 15, 1993
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative studyT Shirasaka, R Yarchoan, M C O'Brien, et al.
Biochemistry|July 17, 1998
Characterization of molecular defects in isovaleryl-CoA dehydrogenase in patients with isovaleric acidemiaA W Mohsen, B D Anderson, S L Volchenboum, et al.
Cancer Gene Therapy|March 18, 2006
Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft modelK-W Peng, E M Hadac, B D Anderson, et al.
Pageof 16

Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
Antimicrobial Agents and Chemotherapy|May 1, 1994
Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteinsS Kageyama, B D Anderson, B L Hoesterey, et al.
American Journal of Human Genetics|March 21, 2000
Exon skipping in IVD RNA processing in isovaleric acidemia caused by point mutations in the coding region of the IVD geneJ Vockley, P K Rogan, B D Anderson, et al.
Annals of the New York Academy of Sciences|January 1, 1983
Immunosuppression by human alpha 2-macroglobulin, a 3800 Mr peptide, and other derivativesW J Hubbard, B D Anderson, A E Balber, et al.
Pediatrics|October 4, 2000
Prospective evaluation of propofol anesthesia in the pediatric intensive care unit for elective oncology procedures in ambulatory and hospitalized childrenJ H Hertzog, H J Dalton, B D Anderson, et al.
The Journal of Infectious Diseases|May 1, 1995
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapyE Kojima, T Shirasaka, B D Anderson, et al.
Journal of Medicinal Chemistry|June 26, 1992
Synthesis and anti-HIV activity of isonucleosidesD M Huryn, B C Sluboski, S Y Tam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2014
The role of age on dose-limiting toxicities in phase I dose-escalation trialsA Schwandt, P J Harris, S Hunsberger, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 15, 1993
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative studyT Shirasaka, R Yarchoan, M C O'Brien, et al.
Biochemistry|July 17, 1998
Characterization of molecular defects in isovaleryl-CoA dehydrogenase in patients with isovaleric acidemiaA W Mohsen, B D Anderson, S L Volchenboum, et al.
Cancer Gene Therapy|March 18, 2006
Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft modelK-W Peng, E M Hadac, B D Anderson, et al.
Pageof 16